Report #2825131

Received Feb 7, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: Age unknown
State: TX
Recovered: Unknown
Vaccinated: Dec 13, 2024
Onset: Jan 12, 2025
Days to onset: 30
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
HEP	HEP B (HEPLISAV-B)	DYNAVAX TECHNOLOGIES CORPORATION	1	945658	IM / RA

Symptoms (2)

Extra dose administeredNo adverse event

Symptom narrative

First Dose Received Heplisav-B, Second Dose Received Engerix-B; Initial report received on 24-Jan-2025. A pharmacist reported that a 19-year-old female (race and ethnicity not provided) received HEPLISAV-B (hepatitis B vaccine) for hepatitis B immunization and was given ENGERIX-B as the second dose. No medical history or concomitant medications were reported. On 13-Dec-2024, the patient received dose 1 of a hepatitis B vaccine [HEPLISAV-B (lot #945658, expiration date 31-Jan-2027, NDC #43528-003-05) was administered intramuscularly in the right deltoid. On 12-Jan-2025, 30 days after having been vaccinated with HEPLISAV-B, the patient was given ENGERIX-B (lot #95BJ9, expiration date 25-Jul-2026, NDC #58160082052) in the left deltoid as the second dose of hepatitis B vaccine. The vaccine was administered at another Pharmacy. No adverse events were reported. No additional information was reported. Company Comment: The company assessed the event as non-serious.; Sender's Comments: The company assessed the event as non-serious.